Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC).

abstract：:Proliferating cell nuclear antigen (PCNA) was detected in the peripheral blood mononuclear cells (PBMC) of patients with malignant lymphoma (ML). Twenty-one of 27 patients with ML had PCNA expressing PBMC (5.25+/-4.75% cells), which tended to increase in the advanced clinical stage of ML. PCNA in PBMC extracts was det...

journal_title：Leukemia & lymphoma

authors： Takahashi T,Takasaki Y,Takeuchi K,Yamanaka K,Oshimi K,Hashimoto H

更新日期：1997-12-01 00:00:00

abstract：:Central venous access devices (CVADs) are used for intravenous therapy in patients with hematological malignancies. There are limited data comparing catheter outcomes in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. A retrospective review comparing the incidence of early and late CVAD-a...

journal_title：Leukemia & lymphoma

authors： Lim MY,Al-Kali A,Ashrani AA,Begna KH,Elliott MA,Hogan WJ,Hook CC,Kaufmann SH,Letendre L,Litzow MR,Patnaik MS,Pardanani A,Tefferi A,Wolanskyj AP,Grill DE,Pruthi RK

更新日期：2013-06-01 00:00:00

abstract：:Disruptions of pathways of programmed cell death, or apoptosis, are increasingly found in malignant cells of both solid and hematologic neoplasms. Caspases belong to a family of cysteine proteases and have emerged as central regulators of the apoptotic cascade. Despite many and diverse signals that can trigger apoptos...

journal_title：Leukemia & lymphoma

authors： Faderl S,Estrov Z

更新日期：2001-02-01 00:00:00

abstract：:Rituximab is a CD20-targeted monoclonal antibody widely used in the treatment of B-cell lymphoma. Previously, we have shown that Epstein-Barr virus (EBV) latent membrane protein-1 (LMP1) increases chemoresistance in malignant cancer cells. In this study we examined the effects of LMP1 on the response of B-cell lymphom...

journal_title：Leukemia & lymphoma

authors： Kim JH,Kim WS,Park C

更新日期：2012-08-01 00:00:00

abstract：:A prospective randomized study on aggressive non-Hodgkin's lymphomas was conducted by investigators at several Italian institutions with the intent of comparing two third-generation conceptually different regimens: the regimen containing methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, ...

journal_title：Leukemia & lymphoma

authors： Mazza P,Zinzani PL,Martelli M,Fiacchini M,Bocchia M,Pileri S,Falini B,Martelli MF,Amadori S,Papa G

更新日期：1995-02-01 00:00:00

abstract：:The 11th International Cord Blood Symposium was devoted to advances in umbilical cord blood (UCB) research and transplant. Results of cord blood transplant (UCB SCT) for congenital storage disease and hemoglobinopathies are encouraging, but UCB SCT may also be useful for older adults with hematologic malignancies, and...

journal_title：Leukemia & lymphoma

authors： van Besien K

更新日期：2014-08-01 00:00:00

abstract：:The role of cyclic AMP (cAMP) as second messenger in erythropoiesis has been suggested in the early 1980s. However, careful analysis showed that cAMP is not generated in direct response to the main erythropoiesis-controlling cytokines such as erythropoietin (Epo). As a result, cAMP disappeared from the central stage i...

journal_title：Leukemia & lymphoma

authors： Boer AK,Drayer AL,Vellenga E

更新日期：2003-11-01 00:00:00

abstract：:In chronic myeloid leukemia (CML), experimental studies using synthetic peptides identical to the bcr-abl fusion region have revealed the capability of specific peptides to bind to human leukocyte antigen (HLA) class I molecules (HLA-A2, A3, A11, B8) and class II molecules (HLA-DR1, DR2, DR3, DR4 and DR11). Individual...

journal_title：Leukemia & lymphoma

authors： Chhaya SU

更新日期：2006-02-01 00:00:00

abstract：:Forty patients, with mainly poor risk haematological malignancies, were given the new regimen FLAG, comprising fludarabine, arabinosyl cytosine and G-CSF. Twenty four patients had acute myeloid leukaemia (AML), 8 patients myelodysplastic syndrome (MDS) and a further 8 patients had a variety of other haematological mal...

journal_title：Leukemia & lymphoma

authors： Nokes TJ,Johnson S,Harvey D,Goldstone AH

更新日期：1997-09-01 00:00:00

abstract：:Aggressive B-cell non-Hodgkin lymphoma (aNHL) accounts for ∼50% of all NHL cases. The only potentially curative, broadly available treatment for patients with relapse, failing frontline treatment, is high-dose therapy followed by autologous stem cell transplantation (ASCT); patients ineligible for/who have failed ASCT...

journal_title：Leukemia & lymphoma

authors： Salles GA,Pettengell R,Cordoba R,Długosz-Danecka M,Jurczak W,Tilly H

更新日期：2019-07-01 00:00:00

abstract：:The mammalian target of rapamycin (mTOR) is an important protein kinase regulating cell survival and apoptosis. To determine whether genetic variations in mTOR are associated with risk of acute lymphoblastic leukemia (ALL) in Chinese children, we genotyped two tag single nucleotide poymorphisms (SNPs) in mTOR (rs2536 ...

journal_title：Leukemia & lymphoma

authors： Huang L,Huang J,Wu P,Li Q,Rong L,Xue Y,Lu Q,Li J,Tong N,Wang M,Zhang Z,Fang Y

更新日期：2012-05-01 00:00:00

abstract：:The single nucleotide polymorphism (SNP) rs16754 of the WT1 gene has been described as a possible prognostic marker in patients with acute myeloid leukemia (AML). However, the results in this field are not reproducible in different cohorts. In this study, we investigated WT1 mutations, expression levels and SNP rs1675...

journal_title：Leukemia & lymphoma

authors： Luo S,Yu K,Yan QX,Shen ZJ,Wu JB,Chen HM,Gao SM

更新日期：2014-02-01 00:00:00

abstract：:The tyrosine kinase inhibitors (TKIs), nilotinib, ponatinib, and dasatinib (but not bosutinib or imatinib), are associated with vascular adverse events (VAEs) in chronic myeloid leukemia (CML). Though the mechanism is inadequately understood, an effect on vascular cells has been suggested. We investigated the effect o...

journal_title：Leukemia & lymphoma

authors： Gover-Proaktor A,Granot G,Pasmanik-Chor M,Pasvolsky O,Shapira S,Raz O,Raanani P,Leader A

更新日期：2019-01-01 00:00:00

abstract：:The increased number of CD5+ B-cells in some human autoimmune diseases, the frequent commitment of CD5+ B-cells to the production of natural autoantibodies, and the apparent involvement of these cells in the pathogenesis of the autoimmune hemolytic anemia (AIHA) in certain mouse models suggests a causal relationship b...

journal_title：Leukemia & lymphoma

authors： Efremov DG,Ivanovski M,Burrone OR

更新日期：1998-01-01 00:00:00

abstract：:The short segments of cDNA encoding glycoprotein (GP)Ib alpha, GPIIb, GPIIIa and platelet factor (PF) 4 were amplified using reverse transcriptase-polymerase chain reaction (RT-PCR) in order to characterize various types of megakaryoblasts. Cell lines with megakaryocytic features (K562, CMK and HEL) were tested. GPIb ...

journal_title：Leukemia & lymphoma

authors： Yasunaga M,Ryo R,Sugano W,Yamaguchi N

更新日期：1992-08-01 00:00:00

abstract：:The MRC has conducted randomised trials in CLL sine 1978: CLL 1 (1978-84), 660 patients; CLL 2 (1984-90), 640 patients; CLL 3 (from June 1990), 90 patients. Centralised morphological diagnosis and membrane marker studies have allowed the exclusion of non-CLL disorders. Some of the treatment questions were repeated in ...

journal_title：Leukemia & lymphoma

authors： Catovsky D,Richards S,Fooks J,Hamblin TJ

更新日期：1991-01-01 00:00:00

abstract：:Primary central nervous system lymphoma (PCNSL) is an aggressive neoplasm with a poor prognosis. Early studies of whole brain radiation therapy (WBRT) alone revealed a robust initial response but high rates of local recurrence with long-term follow-up. The addition of high-dose methotrexate (HDMTX)-based chemotherapy ...

journal_title：Leukemia & lymphoma

authors： Milgrom SA,Yahalom J

更新日期：2015-05-01 00:00:00

abstract：:While more than 75% of the adult patients with acute lymphoblastic leukemia (ALL) achieve a complete remission after treatment with intensive chemotherapy, about 40% of them relapse within five years. These relapses are probably due to residual leukemic cells. Gene rearrangements are used as markers of clonality and t...

journal_title：Leukemia & lymphoma

authors： Knauf WU,Ho AD,Heger G,Hoelzer D,Hunstein W,Thiel E

更新日期：1991-01-01 00:00:00

abstract：:The outcomes of acute promyelocytic leukemia (APL) in pregnancy are largely unknown. The MEDLINE database was systematically searched to obtain 43 articles with 71 patients with new-onset APL during pregnancy. Induction therapy included various regimens of all-trans retinoic acid (ATRA), cytarabine, and anthracycline ...

journal_title：Leukemia & lymphoma

authors： Verma V,Giri S,Manandhar S,Pathak R,Bhatt VR

更新日期：2016-01-01 00:00:00

abstract：:Since etoposide interacts with the nuclear enzyme topoisomerase II, the drug concentrations in the malignant cells during chemotherapy may have clinical correlates. Plasma protein binding of etoposide is extensive (94%) and alterations of the non-proteinbound fraction affect pharmacokinetic behavior of the drug. The p...

journal_title：Leukemia & lymphoma

authors： Liliemark EK,Liliemark J,Pettersson B,Gruber A,Björkholm M,Peterson C

更新日期：1993-07-01 00:00:00

abstract：:The immune cell composition of the follicular lymphoma (FL) tumor microenvironment is increasingly recognized as an important determinant for clinical outcome. Here, we explored frequency and distribution of dendritic cell (DC) subtypes in relation to regulatory T cells (Treg) by immunohistochemistry in lymph node bio...

journal_title：Leukemia & lymphoma

authors： Chevalier N,Mueller M,Mougiakakos D,Ihorst G,Marks R,Schmitt-Graeff A,Veelken H

更新日期：2016-09-01 00:00:00

abstract：:In an attempt to better understand the clinicopathologic features of T- and natural killer (NK)/T-cell lymphomas in Taiwan and the distribution and relative frequency of each subtype according to the new WHO classification, the pathology file of a medical center in southern Taiwan during 1989-2002 was retrospectively ...

journal_title：Leukemia & lymphoma

authors： Lu D,Lin CN,Chuang SS,Hwang WS,Huang WT

更新日期：2004-05-01 00:00:00

abstract：:Bone marrow necrosis (BMN) is a rare pathologic entity associated with a wide variety of diseases. We describe a patient with chronic myeloid leukemia on interferon treatment, who developed BMN with symptoms and signs masquerading as interferon toxicity. This is followed by a literature review of BMN in CML. ...

journal_title：Leukemia & lymphoma

authors： Chim CS,Ma SK,Lam CK

更新日期：1999-04-01 00:00:00

abstract：:Peripheral lymphopenia is a well-known negative prognostic marker in classical Hodgkin lymphoma (cHL). We characterized the peripheral B-cell compartment in a prospective cohort of 83 pediatric cHL patients. We observed significantly low total B-cell counts (<100 cells/µl) in 31 of 83 patients (37%). More specifically...

journal_title：Leukemia & lymphoma

authors： Hamdi L,Creidy R,Boudjemaa S,Hendel-Chavez H,Hugues P,Taoufik Y,Leblanc T,Coulomb A,Krzysiek R,Landman-Parker J,Besson C

更新日期：2020-10-23 00:00:00

abstract：:The etiology of chronic lymphocytic leukemia (CLL) appears to be influenced by genetic factors which may contribute to its differential, gender- and age-specific incidence. The presented study is the first, which investigated the frequencies of DNA-typed alleles of all relevant human leukocyte antigens (HLA) loci in C...

journal_title：Leukemia & lymphoma

authors： Mueller LP,Machulla HK

更新日期：2002-05-01 00:00:00

abstract：:Data from 29,845 patients with lymphomas, 981 of whom had lymphoma as a second primary tumor, registered in the Surveillance Epidemiology and End Results (SEER) program in the U.S.A. between 1973 and 1986 were analyzed. The characteristics of the 274 patients with lymphoma as a second tumor who had received chemothera...

journal_title：Leukemia & lymphoma

authors： Robinson E,Bar-Deroma R,Epelbaum R,Rennert G,Neugut AI

更新日期：1996-01-01 00:00:00

abstract：:Existing prognostic tools for HIV + diffuse large B-cell lymphoma (DLBCL) fail to accurately predict patient outcomes. To develop a novel prognostic algorithm incorporating molecular tumor characteristics and HIV disease factors, we included 80 patients with HIV-related DLBCL diagnosed between 1996 and 2007. Immunohis...

journal_title：Leukemia & lymphoma

authors： Chao C,Silverberg MJ,Chen LH,Xu L,Martínez-Maza O,Abrams DI,Zha HD,Haque R,Said J

更新日期：2018-02-01 00:00:00

abstract：:Thirty-four patients with acute myeloblastic leukaemia were treated with DAC, a schedule containing the nitrosourea CCNU (lomustine) 200 mg/m2 given on day one of treatment, together with a standard "3 + 7" remission induction schedule of daunorubicin (DR) and cytosine arabinoside (Ara-C). The results were compared wi...

journal_title：Leukemia & lymphoma

authors： Barrett AJ,Treleaven JG,Samson DM,Evans M,Gaminara E,Foadi M,McCarthy DM

更新日期：1990-01-01 00:00:00

abstract：:Thirteen patients (pts) with highly refractory acute myeloid leukemia (AML) 10 pts with de novo AML and 3 with blast crisis of chronic myeloid leukemia were treated with carboplatin (CP) 150 mg/m2/day through continuous IV infusion for 7 consecutive days. Seven of them received CP at least as third or more line therap...

journal_title：Leukemia & lymphoma

authors： Delmer A,Bauduer F,Vekhoff A,Rio B,Cymbalista F,Delmas-Marsalet B,Blanc CM,Cadiou M,Broca M,Renoux M

更新日期：1994-10-01 00:00:00

abstract：:We investigated 41 diffuse large B-cell lymphomas (DLBCL) diagnosed at one center harboring ≥50% of latently Epstein-Barr virus (EBV)-infected neoplastic cells occurring in 34 patients aged ≥50 years and in 7 patients younger than 50 years in the absence of any known immunodeficiency for the expression patterns of EBV...

journal_title：Leukemia & lymphoma

authors： Jöhrens K,Trappe RU,Lenze D,Pfreundschuh M,Ziepert M,Hummel M,Anagnostopoulos I

更新日期：2016-12-01 00:00:00